USA flag logo/image

An Official Website of the United States Government

SBIR Phase I:Large Area Scanning a/LCI for Endoscopic Precancer Detection

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
99087
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
1013849
Solicitation Year:
N/A
Solicitation Topic Code:
T13
Solicitation Number:
N/A
Small Business Information
Oncoscope, Inc.
324 BLACKWELL ST, STE 1120 DURHAM, NC 27701-3658
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: SBIR Phase I:Large Area Scanning a/LCI for Endoscopic Precancer Detection
Agency: NSF
Contract: 1013849
Award Amount: $149,920.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project seeks to develop a new clinical instrument capable of using a novel optical technology to scan large areas of epithelial tissue for the detection and localization of precancers. The optical technology, angle-resolved Low Coherence Interferometry (a/LCI) has shown excellent sensitivity and specificity for detecting precancerous lesions during in vivo testing with Barrett's Esophagus patients but has been confined to single point measurements. To have the greatest clinical impact, the modality must be extended to scan wide tissue areas. This project will offer significant advantages due to the unique imaging geometry of the a/LCI approach. While the use of scanning schemes for traditional imaging methods have been investigated, the a/LCI approach relies on measuring the angular distribution of scattered light. Thus, wide area scanning implementations of a/LCI will require a novel optical design to address issues not commonly of interest in imaging. The research plan calls for building a scanning system capable of interrogating at least 5 locations separated by 1 millimeter within one second without repositioning the probe to demonstrate proof-of-concept for the approach. The broader impact/commercial potential of this project centers on the field of early cancer detection and diagnosis. Traditional evaluation of the health of epithelial tissues requires systematic tissue removal with subsequent examination by a pathologist. Biopsy sampling error is a significant problem with early cancerous tissues often eluding detection, as there may not be evidence of disease at the tissue surface. The proposed a/LCI system has the potential to greatly improve endoscopic screening and surveillance of epithelial tissues for precancerous lesions. Interviews with practicing clinicians and feedback from initial field trial sites of the a/LCI technology point to widespread market adoption of this instrument but also identify the preference for automated tissue scanning over the current point imaging modality. The high throughput of the proposed wide area scanning system will provide comprehensive assessments of tissue health in a way that is not possible using histopathological evaluation of excised biopsies. The low cost of the a/LCI system and its ease-of-use will enable widespread applications, a factor which is increasingly valued in the current, fiscally conscious health care environment.

Principal Investigator:

William Brown
PhD
9193231807
wbrown@oncoscope.com

Business Contact:

William Brown
PhD
9193231807
wbrown@oncoscope.com
Small Business Information at Submission:

Oncoscope
324 Blackwell St. Suite 1120 Durham, NC 27701

EIN/Tax ID: 205020734
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No